Muhammad Hassan Bashir, MD | |
725 Welch Rd, Palo Alto, CA 94304-1601 | |
(650) 497-8000 | |
Not Available |
Full Name | Muhammad Hassan Bashir |
---|---|
Gender | Male |
Speciality | Allergy/immunology |
Experience | 21 Years |
Location | 725 Welch Rd, Palo Alto, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1053613711 | NPI | - | NPPES |
GR0043790 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207KA0200X | Allergy & Immunology - Allergy | A115993 (California) | Secondary |
207R00000X | Internal Medicine | A115993 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Community Regional Medical Center | Fresno, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Baz Allergy Asthma And Sinus Center Inc | 6507770716 | 20 |
Premium Urgent Care Inc | 9638306533 | 5 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Entity Name | Baz Allergy Asthma & Sinus Center Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1710906995 PECOS PAC ID: 6507770716 Enrollment ID: O20031112000791 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Entity Name | Stanford Health Care |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Entity Name | Lpch Medical Group Div Of Lucile |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Entity Name | Premium Urgent Care Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1952744070 PECOS PAC ID: 9638306533 Enrollment ID: O20131223000834 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Muhammad Hassan Bashir, MD 725 Welch Rd, Palo Alto, CA 94304-1601 Ph: (650) 497-8000 | Muhammad Hassan Bashir, MD 725 Welch Rd, Palo Alto, CA 94304-1601 Ph: (650) 497-8000 |
News Archive
In a new study from the Danish psychiatry project iPSYCH, researchers have identified genetic risk factors for developing bipolar disorder and psychoses among people with depression.
Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.
Organovo, Inc., a regenerative medicine company focused on bioprinting technology, today announced the release of data on the first fully bioprinted blood vessels. Data was presented at the Tissue Engineering and Regenerative Medicine International Society (TERMIS) meeting in Orlando, Florida. The blood vessels were created through the use of the NovoGen MMX Bioprinter, Organovo's proprietary platform for the creation of 3D tissue constructs.
Those who suffer from common functional gastrointestinal disorders face work productivity losses and impairments in daily activity that amount to the loss of at least one day of work in a 40-hour workweek, according to a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology.
› Verified 4 days ago
Daniel Joseph Razzano, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Mahnoosh Kuhbanani Seifoddini, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Va Palo Alto Health Care System (111stc), Palo Alto, CA 94304 Phone: 209-946-3400 | |
Dr. Yusra Nazar Hussain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 770 Welch Rd, Suite # 250, Palo Alto, CA 94304 Phone: 650-328-1676 Fax: 650-445-0911 | |
Dr. David Yao, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Medical Services (111a), Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Franklin Perry, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2175 Park Blvd, Palo Alto, CA 94306 Phone: 650-330-3688 Fax: 650-330-3686 | |
Dr. Ryan Arthur Mcconnell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2972 | |
Dr. Ann Margaretha Lowe, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 420 Cambridge Ave, Unit 3, Palo Alto, CA 94306 Phone: 650-323-6614 |